Thomas Sciascia - Aug 19, 2024 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role: Chief Scientific Officer
Signature: /s/ Christopher Galletta, attorney-in-fact
Stock symbol: TRVI
Transactions as of: Aug 19, 2024
Transactions value $: -$25,293
Form type: 4
Date filed: 8/21/2024, 04:00 PM
Previous filing: Aug 16, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TRVI	Common Stock	Options Exercise	$23.6K	+16.5K	+7.49%	$1.43	237K	Aug 19, 2024	Direct
transaction	TRVI	Common Stock	Sale	-$48.9K	-16.5K	-6.97%	$2.96	220K	Aug 19, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TRVI	Stock Option (right to buy)	Options Exercise	$0	-16.5K	-100%	$0.00	0	Aug 19, 2024	Common Stock	16.5K	$1.43	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.9000 to $3.0020 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F2	This option was granted on November 25, 2014. The 48,001 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.9000 to $3.0020 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

This option was granted on November 25, 2014. The 48,001 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018.